Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis

BACKGROUND: There are no head-to-head randomised controlled trials (RCTs) comparing the effectiveness of biologics in ulcerative colitis (UC). We aimed to assess the cost-effectiveness of adalimumab, infliximab and vedolizumab as first-line agents to induce clinical remission and mucosal healing (MH...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokomizo, Lauren, Limketkai, Berkeley, Park, K T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860720/
https://www.ncbi.nlm.nih.gov/pubmed/27195130
http://dx.doi.org/10.1136/bmjgast-2016-000093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860720/
https://www.ncbi.nlm.nih.gov/pubmed/27195130
http://dx.doi.org/10.1136/bmjgast-2016-000093

Ejemplares similares